Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: PPD 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: PPD 1Q

Development segment revenue was $335.4 million (-7%). Discovery sciences segment revenue was $5.7 million (-64%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PPD 1Q

1Q Revenues: $364.9 million (-7%)

1Q Earnings:$44.6 million (+11%)

Comments: Development segment revenue was $335.4 million (-7%). Discovery sciences segment revenue was $5.7 million (-64%), which included two milestone payments from Janssen-Cilag totaling $5.0 million. New business authorizations for the quarter totaled $579.7 million. Contract cancellations and adjustments for the quarter were $214.6 million, including a $76.9 million cancellation from a large biotech client for a multinational clinical trial. Backlog at March 31, 2009, was $3.2 billion.

The company has also announced the opening of an office in Tokyo, Japan, expanding its Phase II-IV clinical development services in the Asia-Pacific region. PPD will provide clinical management services in key therapeutic areas from this location. The office strengthens PPD’s operations in Japan, where it has previously worked in the region through a subcontractor.

“Japan offers competitive timelines for site startup and patient enrollment, and the government is making major improvements to streamline drug development, bringing Japan’s regulatory timelines more in line with the rest of the world,” said Fred Eshelman, chief executive officer of PPD. “With our clients increasingly including Japan in their global drug development programs, having a base of operations in Tokyo will enable us to better meet their growing needs.”


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics